FACT 02 Delivers full-body benefits After meals, GLP-1 is released in the small intestine and travels through the body to affect receptors in the brain, stomach, pancreas, heart, and more
For instance, the LEADER trial spotlighted liraglutide, illustrating a noteworthy reduction in cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke over several years
Tambini also outlined the potential risks of these supplements including inconsistent dosages, hidden or harmful ingredients, and the possibility of interfering with other medications
Morton JI, Marquina C, Shaw JE, Liew D, Polkinghorne KR, Ademi Z, et al
In MDD, this peripheral-central coupling is likely amplified by BBB dysfunction characterized by increased permeability, neurovascular inflammation, and associations with symptom severity [172, 173] thereby lowering the threshold at which peripheral KP activation translates into central glutamatergic, oxidative, and neuroimmune dysregulation
